Board of Directors

Mr. King is the Chair of our Board of Directors. He served as Achieve’s interim Executive Chair from August 2024 to June 2025, and as a director since March 2023. Mr. King brings a wealth of knowledge from 40+ years of experience in biopharma leadership positions ranging from large to development-stage companies. He has built, operated and sold multiple public specialty pharmaceutical businesses. Mr. King also serves on the boards of Concentric Analgesics, Inc., and Kinaset Therapeutics, Inc., both clinical stage, privately held biopharmaceutical companies. Previously, Mr. King served on the board of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, acting as interim CEO from December 2017 to April 2018 and interim President from April to May 2018. He was President, CEO, and a board member of Alexza Pharmaceuticals, Inc. from June 2003 to August 2016, when it was acquired by Grupo Ferrer, also serving as CFO and Chief Accounting Officer from October 2015 to August 2016. Prior to this, he was President, CEO, and a board member of Cognetix, Inc., a privately held biopharmaceutical company, from September 2002 to April 2003. At Anesta Corporation, a publicly traded pharmaceutical company, he held various senior roles, including President and COO (1995-1997) and President and CEO (1997-2000), and served on the board until its acquisition by Cephalon, Inc. in October 2000. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.

Mr. Stewart is a co-founder and the President and Chief Executive Officer of Achieve. He is also a director on the Achieve Board of Directors and previously served as Chairman. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single-purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single-purpose central nervous system company, from 2013 to 2014 prior to Brabant Pharma’s acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath.

Dr. Bridget Martell is a high-impact, results-oriented individual with a demonstrated track record in building, financing, and leading highly successful companies. Since 2024, Dr. Martell has served as Operating Partner and Senior Advisor at Two Bear Capital and as an Independent Director at Achieve Life Sciences, Aligos Therapeutics, and Delcath Systems. She has contributed to seven medicine approvals: Komzifti®, Kadcyla®, Elelyso®, Intermezzo®, the Ogiviri® (trastuzumab biosimilars), and expanded indications for Pradaxa® and Sutent®. She previously served as CEO at Artizan Biosciences, where she led a precision medicine drug development platform company out of Yale University focusing on inflammatory disease. Dr. Martell also held numerous other leadership roles at companies including Kura Oncology and Juniper Pharmaceuticals, starting her pharma career at Pfizer. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. Dr. Martell was also a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at Yale Ventures. She holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Mr. Stuart Duty is an experienced financial executive with over 30 years in finance and investment banking building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. His advisory activities spanned a global client base including significant in-country and cross-border transactions in the US, Japan, China, Canada and many European countries. Mr. Duty was a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023. Previously, he held senior roles at Piper Jaffray and Montgomery Securities. Mr. Duty also held operating roles at Oracle Partners as Chief Operating Officer and at Curative Technologies as Director, Business Development. He began his career at Kidder Peabody. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A from Harvard Business School.

Mr. Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.

Dr. Kristen Slaoui is a strategic advisor and board director with more than 25 years of experience and has served as a member of our Board of Directors since January 2025. She most recently served as Chief Corporate Development Officer at Galderma, the world’s largest independent dermatology company, where she led global corporate and business development strategy, overseeing acquisitions, divestitures, partnerships, and portfolio shaping initiatives that supported Galderma’s transformation into a pure-play, growth-oriented dermatology leader. Prior to Galderma, Dr. Slaoui spent over two decades at GSK in roles spanning early-stage drug discovery through senior-level corporate and business development. She began her career in respiratory research, contributing to the discovery of the long-acting muscarinic receptor antagonist that underpins blockbuster therapies including Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She later transitioned into business development, holding positions of increasing responsibility, and ultimately executed more than $40 billion in transactions across R&D-stage and commercial assets, specialty and emerging-market businesses, and consumer health platforms. Dr. Slaoui holds a Ph.D. in Physiology from the Johns Hopkins Bloomberg School of Public Health, where she also served for over a decade as an adjunct assistant professor. She completed her postdoctoral fellowship at the University of Washington and earned a B.S. in Biology and a B.A. in Classical Studies from Gettysburg College. She is an inventor on multiple patents and the author of more than 40 peer-reviewed scientific publications.

Nancy R. Phelan has served as a member of our Board of Directors since January 2025. Ms. Phelan currently serves as Senior Vice President of Marketing & Analytics at Phathom Pharmaceuticals, a biopharmaceutical company focused on gastrointestinal diseases. She has served as a member of the board of directors of Medexus Pharmaceuticals, a specialty pharmaceutical company focusing on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology, since September 2023, and was previously an independent board member of FemmePharma Consumer Healthcare, a pharmaceutical company dedicated to developing treatment options to address diseases and disorders that disproportionately affect women. From May 2024 to October 2025, Ms. Phelan served as Senior Vice President & Head of Customer Engagement at Trinity Life Sciences, a leader in strategy, insights and analytics for the life sciences industry. Prior to that, Ms. Phelan served as Senior Vice President of Indegene, a technology-led healthcare solutions provider. She also previously held roles of increasing responsibility with Novartis, a global leader in developing and delivering innovative medicines for serious diseases, including as Vice President, Business Transformation, Patient Engagement and Integrated Marketing Team Lead from April 2021 to May 2022 and Vice President, Patient and Specialty Services, Neuroscience from June 2002 to April 2021. She served as Chief Executive Officer and Secretary of Adhera Therapeutics, Inc., a company focused on the discovery, development, and commercialization of small molecule drugs, from April 2019 to June 2020 and as a director from October 2018 to June 2020. Ms. Phelan received a BA with Honors from Franklin & Marshall College and completed coursework towards an MBA from Villanova University. She also received certificates from Wharton Executive Education and the Harvard School of Public Health.